Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P020012/S052

Bellafill Dermal Filler

Tiger Aesthetics Medical, LLC · Decision date May 12, 2026

FDA DECISIONP020012/S052

What did the FDA decide?

FDA records P020012/S052 as a supplement to PMA P020012, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 12, 2026.

FDA approval order statement

Approval for changes to bulk mixing equipment during subassembly manufacturing of the Bellafill Dermal Filler device and Bellafill Skin Test accessory
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
General, Plastic Surgery
Decision date
May 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P020012/S052
Regulatory pathway
PMA supplement
Product code
LMH
Decision code
OK30
Decision date
May 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Implant, dermal, for aesthetic use.

Product code
LMH
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P020012/S052 received

    Application receipt date recorded by FDA.

  2. P020012/S052 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P020012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P020012

Product / regulatory recordCompanyPathwayDecision dateSource
SANAEP020012/S051
Tiger Aesthetics Medical, LLCPMA supplementAug 7, 2026FDA

Explore the linked device profile

Other records with product code LMH

Product / regulatory recordCompanyPathwayDecision dateSource
AllerganPMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementNov 4, 2026FDA
Merz North America, Inc.PMA supplementOct 21, 2026FDA
Prollenium Medical Technologies, Inc.PMA supplementOct 14, 2026FDA
saypha ChiQP250021/S002
Croma-Pharma GmbHPMA supplementOct 8, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Tiger Aesthetics Medical, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
555 E. N. Ln. Suite 5000, Bldg. D, Conshohocken, PA, 19428

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records